Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France.
Department of Neuroradiology, CHU Montpellier, FRANCE.
J Neuroradiol. 2022 Jun;49(4):317-323. doi: 10.1016/j.neurad.2022.02.006. Epub 2022 Feb 18.
Mechanical thrombectomies (MT) in patients with large vessel occlusion (LVO) related to calcified cerebral embolus (CCE) have been reported, through small case series, being associated with low reperfusion rate and worse outcome, compared to regular MT. The purpose of the MASC (Mechanical Thrombectomy in Acute Ischemic Stroke Related to Calcified Cerebral Embolus) study was to evaluate the incidence of CCEs treated by MT and the effectiveness of MT in this indication.
The MASC study is a retrospective multicentric (n = 37) national study gathering the cases of adult patients who underwent MT for acute ischemic stroke with LVO related to a CCE in France from January 2015 to November 2019. Reperfusion rate (mTICI ≥ 2B), complication rate and 90-day mRS were systematically collected. We then conducted a systematic review by searching for articles in PubMed, Cochrane Library, Embase and Google Scholar from January 2015 to March 2020. A meta-analysis was performed to estimate clinical outcome at 90 days, reperfusion rate and complications.
We gathered data from 35 patients. Reperfusion was obtained in 57% of the cases. Good clinical outcome was observed in 28% of the patients. The meta-analysis retrieved 136 patients. Reperfusion and good clinical outcome were obtained in 50% and 29% of the cases, respectively.
The MASC study found worse angiographic and clinical outcomes compared to regular thrombectomies. Individual patient-based meta-analysis including the MASC findings shows a 50% reperfusion rate and a 29% of good clinical outcome.
通过小病例系列研究报道了机械血栓切除术(MT)治疗与钙化性脑栓子(CCE)相关的大血管闭塞(LVO)患者,与常规 MT 相比,其再灌注率较低,预后较差。MASC(急性缺血性卒中与钙化性脑栓子相关的机械血栓切除术)研究的目的是评估 MT 治疗 CCE 的发生率以及该适应证中 MT 的有效性。
MASC 研究是一项回顾性多中心(n=37)全国性研究,收集了 2015 年 1 月至 2019 年 11 月期间法国接受 MT 治疗的急性 LVO 相关大血管闭塞伴 CCE 的成年患者的病例。系统收集再灌注率(mTICI≥2B)、并发症发生率和 90 天 mRS。然后,我们通过在 PubMed、Cochrane Library、Embase 和 Google Scholar 中搜索文章,进行了系统评价。Meta 分析用于估计 90 天的临床结果、再灌注率和并发症。
我们从 35 例患者中收集了数据。57%的病例获得了再灌注。28%的患者获得了良好的临床结果。Meta 分析检索到 136 例患者。50%和 29%的患者分别获得了再灌注和良好的临床结果。
MASC 研究发现与常规血栓切除术相比,血管造影和临床结果更差。包括 MASC 研究结果的基于个体患者的荟萃分析显示,再灌注率为 50%,临床结果良好的比例为 29%。